Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02660827 |
Recruitment Status :
Completed
First Posted : January 21, 2016
Results First Posted : January 11, 2019
Last Update Posted : January 26, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 1 Diabetes | Device: Insulin Pump | Not Applicable |
The study will proceed as follows:
Run-in Period - General:
A total of up to 200 subjects (age 2-13) will be enrolled at up to 15 investigational centers (14 in the US, 1 EMEA) in order to reach 120 subjects who will complete the HCL study.
Study Period - At Home:
Following the two week run-in period using the Study Pump (670G), all subjects (age 2-13) will participate in a 3-month study period.
Study Period - Hotel Study Subjects (age 7-13) will participate in a Hotel study (6 days, 5 nights), with the remainder of the study period to be spent at home. Subjects 2-6 years of age are not required to participate in a hotel study. Instead, they will participate in an out-of-home study for 5 consecutive days, 4-6 hours per day.
Continued Access Program Subjects will be given the opportunity to extend use of their study devices for a period of up to 3 years . If subjects choose to participate in the continuation period, they will retain the study devices at the end of study period visit or receive them back in the event they have been returned to study staff already.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 151 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes |
Actual Study Start Date : | April 18, 2016 |
Actual Primary Completion Date : | November 28, 2018 |
Actual Study Completion Date : | February 1, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Hybrid closed loop
All subjects will be wearing the MMT-670G insulin pump, using it with the closed loop algorithm
|
Device: Insulin Pump
Closed Loop Algorithm
Other Name: MMT-670G |
- Age 2-13 Years Old Subjects Change in A1C [ Time Frame: Baseline and end of 3-month study period ]Descriptive analysis of change in A1C from baseline to end of 3-month study period
- Age 2-13 Years Old Subjects Mean Change in % of Time in Euglycemia (70-180 mg/dL) [ Time Frame: baseline and 3 months ]mean change in % of time in Euglycemia (70-180 mg/dL) from baseline to 3 months study period
- Age 2-13 Years Old Subjects Mean Change in % of Time in Hyperglycemia (> 180 mg/dL) [ Time Frame: baseline and 3 months ]mean change in % of time in hyperglycemia (> 180 mg/dL) from baseline to 3 months study period
- Age 2-13 Years Old Subjects Mean Change in % of Time in Hypoglycemia (<70 mg/dL) [ Time Frame: baseline and 3 months ]mean change in % of time in hypoglycemia (< 70 mg/dL) from baseline to 3 months study period
- Age 2-13 Years Old - Number of Severe Hypoglycemic Event [ Time Frame: 3 months ]Number of severe hypoglycemic events occurred during 3-month study period.
- Age 2-13 Years Old - Number of Diabetic Ketoacidosis (DKA) Event [ Time Frame: 3 months ]Number of Diabetic Ketoacidosis (DKA) events occurred during 3-month study period.
- Age 7-13 Years Old Subjects PLGM Performance - Event Rate Without Hypoglycemia at YSI-FST <=65 mg/dL [ Time Frame: Up to 12 hours after the start of PLGM period ]Event rate without Hypoglycemia at YSI-FST <=65 mg/dL among 105 subjects who underwent the PLGM experiments. The event rate without hypoglycemia is the number of experiments without hypoglycemia/total number of experiments and hypoglycemic events are defined based on the occurrence of 2 or more continuous YSI-FST <= 65mg/dL during in-clinic procedures.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years to 13 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
General Inclusion Criteria
- Subject is age 2-13 years at time of screening
- Subject has a clinical diagnosis of type 1 diabetes for 1 year or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
-
Subject age 2-6 years has a clinical diagnosis of type 1 diabetes for 3 months or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
Study-specific inclusion criteria
- Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units
- Subjects 7-13: Subjects and their parent(s)/guardian(s) are willing to participate in an overnight visit at the end of the run-in period.
- Subject 7-13 years of age and their parent(s)/guardian(s) are willing to participate in a hotel study for the specified duration of hotel stay.
- Subject 2-6 years of age and their parent(s)/guardian(s) are willing to participate in an extended visit during the study period to perform Frequent Sample Testing.
- Subject must have companion 18 years or older who will sleep in the same dwelling place every night during the study period. This requirement may be verified by subject report at screening visit.
- Subject is willing to perform ≥ 4 finger stick blood glucose measurements daily
- Subject is willing to perform required sensor calibrations
- Subject is willing to wear the system continuously throughout the study
- Subject has a Glycosylated hemoglobin (A1C) value less than 10.0% (as processed by Central Lab) at time of screening visit Note: All HbA1C blood specimens will be sent to and tested by a NGSP certified Central Laboratory. A1C testing must follow National Glycohemoglobin Standardization Program (NGSP) standards.
- Subject has TSH in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range.
- Subject 7 -13 years of age has had pump therapy for greater than 6 months prior to screening (with or without CGM experience)
- Subject 2-6 years of age has had pump therapy for greater than 90 days prior to screening (with or without CGM experience)
- Subjects and their parent(s)/guardian(s) are willing to upload data from the study pump; must have Internet access and a computer system that meets the requirements for uploading the study pump
- If subject has celiac disease, it has been adequately treated as determined by the investigator
-
Subjects and their parent(s)/guardian(s) are willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)
- Humalog® (insulin lispro injection)
- NovoLog® (insulin aspart)
- Subjects and their parent(s)/guardian(s)/companions must be able to speak and be literate in English as verified by the investigator
Exclusion Criteria:
-
Subject has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening:
- Medical assistance (i.e. Paramedics, Emergency Room ( ER) or Hospitalization)
- Coma
- Seizures
- Subject is unable to tolerate tape adhesive in the area of sensor placement
- Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)
- Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
- Subject has a cardiovascular condition which the investigator determines should exclude the subject, i.e. ventricular rhythm disturbance, hypertrophic cardiomyopathy
- Subject is being treated for hyperthyroidism at time of screening
- Subject has diagnosis of adrenal insufficiency
- Subject 7-13 years of age has had DKA in the 6 months prior to screening visit.
- Subject 2-6 years of age has had DKA in the 3 months prior to screening visit
- Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study
- Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks
- Subject 7-13 years of age has been hospitalized or has visited the ER in the 6 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes
- Subject 2-6 years of age has been hospitalized or has visited the ER in the 3 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes
- Subject is currently abusing illicit drugs
- Subject is currently abusing marijuana.
- Subject is currently abusing prescription drugs
- Subject is currently abusing alcohol
- Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of screening
- Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator
- Subject has elective surgery planned that requires general anesthesia during the course of the study
- Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening
- Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation
- Subject diagnosed with current eating disorder such as anorexia or bulimia
- Subject has been diagnosed with chronic kidney disease that results in chronic anemia
- Subject has a hematocrit that is below the normal reference range of lab used.
- Subject is on dialysis
- Subject has serum creatinine of >2 mg/dL.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02660827
United States, California | |
AMCR Institute | |
Escondido, California, United States, 92025 | |
Stanford Hospital and Clinics | |
Palo Alto, California, United States, 94305 | |
SoCal Diabetes | |
Torrance, California, United States, 90505 | |
United States, Colorado | |
Barbara Davis Center | |
Aurora, Colorado, United States, 80045 | |
United States, Florida | |
Nemours Children's Clinic | |
Jacksonville, Florida, United States, 32207 | |
University of South Florida - USF Health | |
Tampa, Florida, United States, 33620 | |
United States, Georgia | |
Atlanta Diabetes Associates | |
Atlanta, Georgia, United States, 30318 | |
United States, Idaho | |
Rocky Mountain Diabetes and Osteoporosis Center | |
Idaho Falls, Idaho, United States, 83404 | |
United States, Indiana | |
Indiana University | |
Indianapolis, Indiana, United States, 46202 | |
United States, Michigan | |
University of Michigan | |
Ann Arbor, Michigan, United States, 48109 | |
Israel | |
Sheba Medical Center | |
Tel Aviv, Israel |
Documents provided by Medtronic Diabetes:
Responsible Party: | Medtronic Diabetes |
ClinicalTrials.gov Identifier: | NCT02660827 |
Other Study ID Numbers: |
CEP 302 |
First Posted: | January 21, 2016 Key Record Dates |
Results First Posted: | January 11, 2019 |
Last Update Posted: | January 26, 2022 |
Last Verified: | January 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Autoimmune Diseases Immune System Diseases Insulin Hypoglycemic Agents Physiological Effects of Drugs |